Editing Ketamine (section)

== Research ==
Ketamine is under investigation for its potential in treating treatment-resistant depression.<ref>{{Cite web |vauthors=Grinspoon P |date=9 August 2022 |title=Ketamine for treatment-resistant depression: When and where is it safe? |url=https://www.health.harvard.edu/blog/ketamine-for-treatment-resistant-depression-when-and-where-is-it-safe-202208092797 |access-date=6 September 2022 |website=Harvard Health |language=en |archive-date=31 August 2022 |archive-url=https://web.archive.org/web/20220831012716/https://www.health.harvard.edu/blog/ketamine-for-treatment-resistant-depression-when-and-where-is-it-safe-202208092797 |url-status=live }}</ref><ref>{{Cite web |title=New Hope for Treatment-Resistant Depression: Guessing Right on Ketamine |url=https://www.nimh.nih.gov/about/director/messages/2019/new-hope-for-treatment-resistant-depression-guessing-right-on-ketamine |access-date=6 September 2022 |website=National Institute of Mental Health (NIMH) |date=13 August 2019 |language=en |archive-date=10 September 2022 |archive-url=https://web.archive.org/web/20220910063011/https://www.nimh.nih.gov/about/director/messages/2019/new-hope-for-treatment-resistant-depression-guessing-right-on-ketamine |url-status=live }}</ref><ref>{{cite journal | vauthors = Pérez-Esparza R | title = Ketamine for Treatment-Resistant Depression: a New Advocate | journal = Revista de Investigacion Clinica | volume = 70 | issue = 2 | pages = 65–67 | date = 2018 | pmid = 29718013 | doi = 10.24875/RIC.18002501 | doi-access = free | title-link = doi }}</ref> Ketamine is a known [[psychoplastogen]], which refers to a compound capable of promoting rapid and sustained [[neuroplasticity]].<ref>{{cite journal |vauthors=Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS |date=August 2010 |title=mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists |url=https://www.neuroplasticitymd.com/ |journal=Science |volume=329 |issue=5994 |pages=959–964 |bibcode=2010Sci...329..959L |doi=10.1126/science.1190287 |pmc=3116441 |pmid=20724638 |archive-date=16 January 2025 |access-date=16 January 2025 |archive-url=https://web.archive.org/web/20250116052625/https://neuroplasticitymd.com/ |url-status=dead }}</ref> In a [[rat]] model of depression, [[psilocybin]] and [[LSD]] produced longer-lasting antidepressant-like effects than ketamine, suggesting they may offer more persistent therapeutic benefits.<ref name="acschemneuro.9b00493">{{cite journal | vauthors = Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD | title = Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression | journal = ACS Chemical Neuroscience | volume = 11 | issue = 6 | pages = 864–871 | date = March 2020 | pmid = 32133835 | doi = 10.1021/acschemneuro.9b00493 | s2cid = 212418003 | doi-access = free | title-link = doi }}</ref> <!-- Recreational use and Adverse effects -->

Ketamine has shown [[anthelmintic]] activity in rats, with an effect comparable to [[ivermectin]] and [[albendazole]] at extremely high concentrations.<ref>{{cite journal | vauthors = Ferreira SR, Machado AR, Furtado LF, Gomes JH, de Almeida RM, de Oliveira Mendes T, Maciel VN, Barbosa FS, Carvalho LM, Bueno LL, Bartholomeu DC, de Araújo JV, Rabelo EM, de Pádua RM, Pimenta LP, Fujiwara RT | title = Ketamine can be produced by Pochonia chlamydosporia: an old molecule and a new anthelmintic? | journal = Parasites & Vectors | volume = 13 | issue = 1 | pages = 527 | date = October 2020 | pmid = 33081837 | pmc = 7574484 | doi = 10.1186/s13071-020-04402-w | doi-access = free | title-link = doi }}</ref>